All In Biotech

Drug Trial Radar · NCT04371627

Viaskin® Peanut (DBV712) Expanded Access Protocol

Viaskin® Peanut (DBV712) Expanded Access Protocol in Peanut-Allergic Children

Last checked: Nov 19, 2026Latest source record: May 28, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

No longer available

Status

No longer available

Enrollment

Not stated

Start

Not stated

Primary completion

Not stated

Sponsor

Lead sponsor
DBV TechnologiesIndustry
Sponsor type
Industry
First posted
May 1, 2020

More drug trials from this sponsor

Design

Study type
Expanded access
Who can join
All sexes, from 4 years, up to 12 years

Summary

As written by the sponsor on the registry.

This is an open label expanded access program for male and female patients ≥ 4 years old.

Conditions

  • Peanut Allergy

Interventions

  • Viaskin PeanutDrug

    Daily epicutaneous delivery

Primary outcomes

What the sponsor says the trial is designed to measure.

No primary outcomes listed.

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.